| NCT06443151 | Role of Endothelial Function in SCI CVD Risk | Craig Hospital | | - Age 18 - 89 yrs
- Level T2-S5
AIS A, B- ≥ 12 months
- NOT have a history of high cholesterol, diabetes (type I or II), obstructive pulmonary disease, chronic kidney or liver disease, cance, autoimmune disease
| Recruiting | 60 | | Drug | General health | | 0 days | 01 September 2024 | 05 June 2024 | 1 | |
| NCT06452264 | Early Intervention for Information Processing Speed Deficits in Acute SCI: A Pilot Study | Kessler Foundation | | - Age 18 - 65 yrs
- Level C1-S5
AIS - ≤ 6 months
| Recruiting | 20 | NA | Rehabilitation | General health | - Quality of Life Index (QLI) - SCI Version
| 25 weeks | 19 June 2024 | 11 June 2024 | 1 | |
| NCT06455137 | Epidural Electrical Stimulation for Spinal Cord Injury Patients and Corticospinal Motor Circuit Improvement | Buddhist Tzu Chi General Hospital | | - Age 20 - 70 yrs
- Level C1-S5
AIS A, B, C, D- ≥ 1 years
- NOT have an active cancer diagnosis
| Recruiting | 20 | NA | Surgery | Mechanism of action | - Action Research Arm Test (ARAT)
- American Spinal Injury Association Impairment Scale (AIS): International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)
- Ashworth and Modified Ashworth Scale (MAS)
- Barthel Index (BI)
- Berg Balance Scale (BBS)
- Box and Block Test (BBT)
- Spinal Cord Independence Measure (SCIM)
- Walking Index for Spinal Cord Injury (WISCI) and WISCI II
- World Health Organization Quality of Life- BREF (WHOQOL-BREF)
| 24 months | 30 April 2024 | 12 June 2024 | 1 | |
| NCT06463418 | Exoskeleton Training for Spinal Cord Injury Neuropathic Pain (ExSCIP) | University College Dublin | | - Age 18 - 65 yrs
- Level C1-S5
AIS - ≥ 6 months
| Recruiting | 40 | NA | | Pain | - International Spinal Cord Injury Pain Classification (ISCIP)
- Neuropathoc Pain Symptom Inventory (NPSI)
| 6 months | 20 December 2024 | 17 June 2024 | 1 | |
| NCT06464744 | Efficacy of rTMS Treatment After Spinal Cord Injury | Oslo University Hospital | | - Age 18 - 80 yrs
- Level C4-T12
AIS C, D- All
- NOT have implanted devices such as cardiac pacemaker and neurostimulator and cochlear implants
- NOT have an active cerebral tumor
- NOT have a history of epilepsy or ongoing epilepsy
- NOT have a history of treatment with Deep Brain Stimulation (DBS)
| Recruiting | 20 | NA | Technology | Standing/walking/mobility | - 10 Meter Walking Test (10 MWT)
- Ashworth and Modified Ashworth Scale (MAS)
- Motor Evoked Potentials (MEPs)
- Pain Numeric Rating Scale (NRS)
- Pendulum Test (Wartenberg)
| 12 weeks | 15 January 2024 | 18 June 2024 | 1 | |
| NCT06268093 | The Therapeutic Effect of Thalidomide in Syringomyelia | Xuanwu Hospital, Beijing | Single Group Assignment | - Age 18 - 80 yrs
- Level C1-S5
AIS - All
- NOT have a history of psychiatric diseases or seizures
- NOT have transplanted organs
- HAVE had surgical treatment of syringomyelia that was ineffective, or
- HAVE syringomyelia and have contraindications to surgical treatment
| Recruiting | 30 | Phase 2 | Drug | General health | - Adverse Events (AEs)
- American Spinal Injury Association Impairment Scale (AIS): International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)
- Pain Visual Analog Scale (VAS)
- Surface Electromyography (sEMG)
| 3 months | 01 February 2024 | 20 February 2024 | 1 | |
